Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 2/20 | 0.35 |
| ▸ | HTR1B | P28222 | 2/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 7/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4518034 | 1.00 | HTR1D (0.35) | HTR1DHTR1BCTSLIDH1P2RX3 | |
| SCHEMBL13763255 | 0.90 | CTSL (0.34) | HTR1DHTR1BCTSLIDH1GRM2 | |
| SCHEMBL4522276 | 0.90 | CTSL (0.35) | HTR1DHTR1BCTSLIDH1P2RX3 | |
| SCHEMBL4522278 | 0.90 | CTSL (0.35) | HTR1DHTR1BCTSLIDH1P2RX3 | |
| SCHEMBL4516372 | 0.90 | P2RX3 (0.34) | CTSLIDH1P2RX3KDM4C | |
| SCHEMBL4516368 | 0.90 | P2RX3 (0.34) | CTSLIDH1P2RX3KDM4C | |
| SCHEMBL4230119 | 0.88 | GRM5 (0.33) | CTSLP2RX3KDM4C | |
| SCHEMBL4515171 | 0.83 | LTA4H (0.36) | HTR1DHTR1BIDH1KDM4CFAAH | |
| SCHEMBL13763361 | 0.82 | CTSL (0.34) | HTR1DHTR1BCTSLIDH1GRM2 | |
| SCHEMBL4508746 | 0.82 | KDM4C (0.41) | HTR1DHTR1BIDH1KDM4CFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203744-A1 | NOVEL PYRIDINE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-08-13 | — | — | US | claimed |
| US-20090203744-A1 | NOVEL PYRIDINE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-08-13 | — | — | US | disclosed |
| WO-2007029062-A2 | NOVEL PYRIDINE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203744-A1 | NOVEL PYRIDINE DERIVATIVES | CYP3A4, CYP4B1, CYP3A5 | HTR1D 562/4885HTR1B 635/4885CTSL 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.